Clinical Trials

184 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07472868 2026-03-16

MEND-IT II

394 enrolled

Pathologic Complete Response

NCT07474103 2026-03-16

SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC

Phase NA Recruiting

49 enrolled

Rectal Neoplasms

NCT00905047 2026-03-13

COLOCROSS

Phase 3 Completed

89 enrolled

Colonic Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

204 enrolled

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07468630 2026-03-12

TRIUNITE-08

106 enrolled

Phase 3 Active not recruiting

Colonic Neoplasms

NCT01918527 2026-03-10

Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer

250 enrolled

Colonic Neoplasms

NCT04333706 2026-03-10

EMPOWER

Phase 1/2 Recruiting

65 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT07112053 2026-03-09

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

40 enrolled

Anatomic Stage IV Breast Cancer AJCC v8

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT05731726 2026-03-05

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

50 enrolled

Rectal Neoplasms

NCT07303283 2026-03-05

Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma

218 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

263 enrolled

Breast Neoplasms

NCT02669173 2026-02-23

Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

Phase 1 Completed

12 enrolled

CNS

Brain Neoplasms, Glioblastoma, Recurrence

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

30 enrolled

Breast Neoplasms, Meningeal Neoplasms

NCT07417241 2026-02-18

SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study

100 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT05171660 2026-02-17

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

446 enrolled

Colorectal Neoplasms

NCT06291064 2026-02-17

TARMAC

85 enrolled

Phase 3 Not yet recruiting

Triple Negative Breast Neoplasms

NCT07113275 2026-02-12

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer

435 enrolled

Rectal Neoplasms

NCT07340541 2026-02-09

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05412082 2026-02-06

SMART TNT

Phase 1 Recruiting

25 enrolled

Locally Advanced Rectal Cancer

NCT07392320 2026-02-06

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

142 enrolled

Nasopharangeal Cancer

NCT05062889 2026-02-03

ERASE-CRC

Phase 2 Suspended

477 enrolled

Colonic Neoplasms

NCT05838391 2026-02-03

Adaptive Radiation in Anal Cancer

Phase NA Recruiting

20 enrolled

Anus Neoplasms

NCT07383285 2026-02-03

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

106 enrolled

Rectal Neoplasms Malignant

NCT04495088 2026-02-02

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer

550 enrolled

Rectal Neoplasms

NCT06958328 2026-02-02

LAP100

356 enrolled

Pancreatic Neoplasms

NCT07381777 2026-02-02

IMMUNOSTAR

270 enrolled

Locally Advanced Rectal Cancer (LARC)

NCT06123338 2026-01-29

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

49 enrolled

Phase 3 Active not recruiting

Esophageal Neoplasms

NCT03399110 2026-01-27

XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)

1,024 enrolled

Stomach Neoplasms

NCT06281405 2026-01-27

TORCH-iTNT

192 enrolled

Phase 2/3 Not yet recruiting

Locally Advanced Rectal Cancer

NCT07366840 2026-01-26

BRIGHT

268 enrolled

Breast Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2 Completed

140 enrolled 32 charts

Phase 2 Active not recruiting

Breast Neoplasms

NCT05807880 2026-01-23

ALTER-HN005

59 enrolled

Head & Neck

Nasopharyngeal Neoplasms

NCT07222215 2026-01-22

CAPELA

297 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT03257163 2026-01-20

Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer

40 enrolled

Stomach Neoplasms

NCT05693766 2026-01-20

INSIGHT

64 enrolled

Breast Neoplasms

NCT03801876 2026-01-14

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

300 enrolled

Phase 1 Active not recruiting

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT04523818 2026-01-14

Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma

25 enrolled

Phase 4 Not yet recruiting

Clinical Stage I Gastric Cancer AJCC v8

NCT07094893 2026-01-14

ARIEL-ENGIC

280 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Phase NA Enrolling by invitation

Breast Neoplasms

NCT07334587 2026-01-12

Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma

248 enrolled

Colorectal Neoplasms

NCT04095299 2026-01-08

WW3

162 enrolled

Phase 1/2 Active not recruiting

Rectal Neoplasms

NCT04564898 2026-01-08

TriComB

48 enrolled

Phase EARLY_PHASE1 Active not recruiting

Colorectal Cancer Metastatic

NCT05108428 2026-01-08

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

20 enrolled

Colonic Neoplasms, Rectal Neoplasms

NCT07229846 2026-01-08

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

30 enrolled

Colorectal Neoplasms

NCT06105684 2026-01-07

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

40 enrolled

Breast Neoplasms

NCT07068763 2026-01-06

mRCAT-E

52 enrolled